XPNPEP2 elisa pair set

XPNPEP2 Matched ELISA Antibody Pair Set, Human

Cat. Num. AAA8118412

• Synonyms: XPNPEP2; XPNPEP2 Matched ELISA Antibody Pair Set; Human; Human XPNPEP2 ELISA Pair Set; X-prolyl aminopeptidase (aminopeptidase P) 2; membrane-bound; AEACEI Matched ELISA Antibody Pair Set; APP2 Matched ELISA Antibody Pair Set; XPNPEP2 elisa pair set

• Specificity: Quantitative determination of Human XPNPEP2

• Assay Type: Solid Phase Sandwich ELISA
• Detection Range: 10.94-700pg/mL
• Sensitivity: 11pg/ml
• Materials Provided: 1. Capture Antibody 1.0 mg/mL of rabbit anti-XPNPEP2 monoclonal antibody (in PBS, pH 7.4). Dilute to a working concentration of 2ug/mL in CBS before coating. ; 2. Detection Antibody 0.5 mg/mL rabbit anti-XPNPEP2 monoclonal antibody conjugated to horseradish-peroxidase (HRP) (in PBS, 50 % glycerol, pH 7.4). Dilute to working concentration of 0.5ug/mL in detection antibody dilution buffer before use. ; 3. Standard Each vial contains 20 ng of recombinant XPNPEP2. Reconstitute with 1 mL detection antibody dilution buffer. After reconstitution, store at -20 degree C to -80 degree C in a manual defrost freezer. A seven-point standard curve using 2-fold serial dilutions in sample dilution buffer, and a high standard of 0.7ng/mL is recommended.
• Preparation and Storage: Capture Antibody: Aliquot and store at -20 degree C to -80 degree C for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.; Detection Antibody: Protect it from prolonged exposure to light. Aliquot and store at -20 degree C to -80 degree C and for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.; Standard: Store lyophilized standard at -20 degree C to -80 degree C for up to 6 months from date of receipt. Aliquot and store the reconstituted Standard at -80 degree C for up to 1 month. Avoid repeated freeze-thaw cycles.

Testing Data

Related Product Information for XPNPEP2 elisa pair set

Aminopeptidase P (APP) is a hydrolase specific for N-terminal imido bonds, which are common to several collagen degradation products, neuropeptides, vasoactive peptides, and cytokines. A membrane-bound and soluble form of this enzyme (XPNPEP2) have been identified as products of two separate genes. XPNPEP2, the X-linked gene that encodes membranous aminopeptidase P (APP), has been reported to associate with APP activity. The membrane aminopeptidase P (XPNPEP2) is largely limited in distribution to endothelia and brush border epithelia. APP and XPNPEP2 contain homologous blocks of sequence common to members of the "pita bread-fold" protein family, of which Escherichia coli methionine aminopeptidase is the prototype. The C-2399A variant in XPNPEP2 is associated with reduced APP activity and a higher incidence of AE-ACEi. XPNPEP2 mRNA was detected in fibroblasts that carry the translocation, suggesting that this gene at least partially escapes X inactivation. XPNPEP2 is a candidate gene for premature ovarian failure (POF).

This XPNPEP2 Matched ELISA Antibody Pair Set, Human is a solid phase sandwich ELISA for quantitative determination of Human XPNPEP2. It contains Human XPNPEP2 capture antibody, Human XPNPEP2 detector antibody (HRP) and a highly purified HEK293-expressed recombinant Human XPNPEP2 protein.

References

Sprinkle TJ, et al. (2000) Cloning, chromosomal sublocalization of the human soluble aminopeptidase P gene (XPNPEP1) to 10q25.3 and conservation of the putative proton shuttle and metal ligand binding sites with XPNPEP2. Arch Biochem Biophys. 378(1): 51-6.Prueitt RL, et al. (2000) Physical mapping of nine Xq translocation breakpoints and identification of XPNPEP2 as a premature ovarian failure candidate gene. Cytogenet Cell Genet. 89(1-2): 44-50.Duan QL, et al. (2005) A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet. 77(4): 617-26.Woodard-Grice AV, et al. (2010) Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 20(9): 532-6.